About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Diabetes Clinical Trials | 7,874 Studies Recruiting | Clareo Health

Clinical TrialsDiabetes

Diabetes Clinical Trials

Browse 7,874 clinical trials for diabetes. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3041-3060 of 7,874 trials

COMPLETEDPhase 2

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

NCT04956263

This is an inpatient treatment, double-blind, randomized, 3-way crossover study in T1DM subjects using insulin pump therapy.

DiabetesDiabetes Mellitus, Type 1Type1diabetes+1 more

Youngene Therapeutics Inc., Ltd.19 participantsStarted Jun 2021

Chula Vista, California, United States

Hematocrit Effect on a Blood Glucose Monitor

NCT05158478

This study assesses the repeatability precision of a blood glucose monitoring system pursuant to ISO 15197

Diabetes Mellitus

Institut fur Diabetes Karlsburg GmbH1 participantsStarted Feb 2022

Karlsburg, Mecklenburg-Vorpommern, Germany

Related Searches

type 2 diabetestrials type 1 diabetestrials t2dtrials t1dtrials

Data from ClinicalTrials.govTerms

Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

NCT05477017

The aim of the study is to evaluate the benefits, documented in experimental settings, of treatment with SGLT2-i in subjects with type 2 diabetes and older than 70 years in normal clinical practice. The type of study does not involve immediate risks or direct benefits for the subjects taking part in it. The potential benefits for clinicians and healthcare systems are: greater knowledge of diabetic disease and the study of new treatment options. However, the analysis of the data will allow us to better identify which patients benefit most from treatment with glycosurics.

University of Milan800 participantsStarted Sep 2022

COMPLETEDPhase 1

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

NCT05411965

To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.

Diabetes Mellitus, Type 2

Boryung Pharmaceutical Co., Ltd48 participantsStarted Apr 2022

Seoul, Gwanakgu, South Korea

WITHDRAWNPhase 3

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

NCT03766750

The purpose of this study is to evaluate the efficacy and safety of Lima association in the control of type 2 diabetes mellitus

Type2 Diabetes Mellitus

EMSStarted Dec 2021

The Association Between Body Constitution and Meridian Energy in Prediabetes

NCT05475587

Traditional Chinese medicine (TCM) theories assert that body constitution and meridian energy are the foundations for disease prevention. However, few studies have incorporated TCM concepts into risk factors. This study aimed to examine the association between body constitution and meridian energy in individuals with prediabetes. We conducted a matched case-control study that included 60 individuals with prediabetes. Finally, the reseachers have found that body constitution may be a risk factor fpr progression to type 2 diabetes mellitus in individuals with prediabetes.

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation60 participantsStarted Jan 2019

New Taipei City, Taiwan

Randomized Clinical Trial of Lifestyle Interventions to Prevent Diabetes in Women With Previous Gestational Diabetes

NCT02327286

Randomized trial aiming to investigate the effectiveness of a lifestyle intervention program implemented within the first year after a pregnancy complicated by gestational diabetes (GDM), in delaying or preventing the development of type 2 diabetes.

Diabetes MellitusDiabetes, Gestational

Federal University of Rio Grande do Sul473 participantsStarted Jan 2015

Fortaleza, Ceará, Brazil • Pelotas, Rio Grande do Sul, Brazil • Porto Alegre, Rio Grande do Sul, Brazil

Association of Bisphenol A,Paraben Exposure and Type 2 Diabetes

NCT05177250

The aim of this study is to evaluate the association between BPA , paraben levels and type 2 DM patients

Type2 DiabetesBisphenol A

Cairo University100 participantsStarted Feb 2022

Impact of Therapeutic Education, Being Set up Under the Authorized Program for Diabetics Patients in Hospital

NCT02461511

To Assess the impact of therapeutic education on: * the occurrence of long term diabetes complications . * balance of his diabetes

Diabetes Complications

Hôpital Léon BérardStarted Mar 2015

Study of Acceptability of a New Distance-learning Tool "MyFIT"

NCT04512885

The investigators developed an on-line learning tool "MyFIT" enabling to patients with T1D to acquire the knowledge and skills for practicing functional insulin therapy from their home. The aim of the present study is to evaluate the acceptability of this new learning modality via the tool "MyFIT" by the patients and by the health professionnals.

Central Hospital, Nancy, France35 participantsStarted Jul 2020

COMPLETEDPhase 2

Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes

NCT04531631

Diabetes is a disorder of energy energy metabolism. Glucose is the main energy substrate for generation of ATP to maintain cellular metabolism, structure and function. Glucokinase (GK) serves as a glucose sensor for the initiation of the energy generation.for energy metabolism. Dorzagliatin is a novel, first-in-class, dual-acting allosteric GK activator (GKA). It increases the affinity of GK for glucose by directly binding a pocket distal to its active site, thus lowering the set point for glucose-stimulated insulin secretion in the beta-cell. Dorzagliatin is a new drug which acts as GK sensor activator (GKA). It can restore the sensitivity of the pancreas cells to glucose and improve glucose control. The drug has been trialled in healthy volunteers and in individuals with type 2 diabetes. The aim of this study is to understand the way in which dorzagliatin works to improve blood sugar control in people with diabetes. The study will look at how dorzagliatin affects insulin secretion and the sensitivity of the pancreas to changes in blood sugar levels. We will examine whether dorzagliatin can restore the function of this GK sensor in patients with known mutations. In a cross-over study, we will evaluate the effects of dorzagliatin, a specific GKA versus placebo in terms of insulin secretion and beta-cell glucose sensitivity in patients with newly-diagnosed T2D and patients who are known heterozygous carriers of GK mutations.

Diabetes Mellitus, Type 2

Chinese University of Hong Kong18 participantsStarted Sep 2020

Hong Kong, Hong Kong

COMPLETEDEARLY Phase 1

Epigenetic and Microbiota Modifications

NCT05076656

In order to investigate how gut microbiota interventions are able to change gut microbiota population and impact insulin resistance, 30 type2 diabetes volunteers with obesity will be randomized to one of the three treatment groups: 1) probiotics arm, who will take a Lactobacillus fermentum D3 in pills daily; 2) FMT arm, who will take a lyophilized fecal microbiota transplant in pills; and 3) control group, who will take placebo pills. After 3 months, insulin resistance, glucose metabolism parameters, and gut microbiota variation will be assessed.

Diabetes type2Obesity

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud22 participantsStarted Jun 2019

RECRUITINGPhase 2

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

NCT05469659

This multicenter, randomized, open-label, controlled study will assess the efficacy of the SGLT2 inhibitor tofogliflozin on Urine Albumin-to-Creatinine Ratio (UACR) compared to metformin in patients with type 2 diabetes with chronic kidney disease (CKD).

T2DM (Type 2 Diabetes Mellitus)MetforminSGLT2-Inhibitors

Shinshu University120 participantsStarted Sep 2021

Matsumoto, Nagano, Japan

Home Telemedicine to Optimize Health Outcomes in High-Risk Youth With Type 1 Diabetes

NCT03324438

This study addresses the critical need for improving Type 1 Diabetes (T1D) health outcomes in high-risk youth (A1C=9-12%; ages 10-17 yrs) (AIC: glycated hemoglobin) where suboptimal glycemic control has severe acute and long-term complications with potentially life threatening consequences. Lack of regular contact with T1D care providers, continued T1D nonadherence, and suboptimal behavioral and mental health functioning compromises the physical health of youth with T1D and the ability of T1D teams to provide effective treatment. If the aims of this study are achieved, this study will change T1D care practices by providing high-risk youth with T1D, and their parents, medical and behavioral health support via home telehealth intervention. This has the potential to significantly change access to T1D care, decrease time spent in hyperglycemia, reduce the frequency of hospital admissions, and improve glycemic control. In addition, this study's use of Multiphase Optimization Strategy (MOST), a highly efficient experimental strategy to determine effective intervention components, should be generalizable to all individuals with T1D, leading to cost-effective, home telehealth intervention programs. Innovative aspects include: 1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.

Type 1 Diabetes Mellitus

University of Colorado, Denver108 participantsStarted Nov 2017

Aurora, Colorado, United States

COMPLETEDPhase 3

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02863419

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S711 participantsStarted Aug 2016

Birmingham, Alabama, United States • Los Alamitos, California, United States • San Diego, California, United States +105 more locations

COMPLETEDPhase 3

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

NCT02906930

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S703 participantsStarted Sep 2016

Lancaster, California, United States • Los Angeles, California, United States • Montclair, California, United States +102 more locations

Physical Activity Intervention for Gestational Diabetes

NCT03664089

Gestational diabetes mellitus (GDM) portends an immediate, increased risk for Type 2 diabetes mellitus (T2DM). The increased risk associated with having GDM is compounded by excess weight retention. Therefore, the weeks and months immediately after a GDM-complicated pregnancy present an optimal window to initiate lifestyle changes to prevent or delay T2DM. The long-term goal is to prevent T2DM among women with GDM. This study's objective is to evaluate the efficacy of a novel, yet simple, activity-boosting intervention on weight loss among women with GDM.

Gestational Diabetes

Sarah Keim75 participantsStarted Sep 2018

Columbus, Ohio, United States

COMPLETEDPhase 4

Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana

NCT03088410

The purpose of this study is to assess the early longitudinal metabolic effects including insulin sensitivity in HIV-exposed uninfected (HEU) children compared to HIV-unexposed uninfected (HUU) children; as well as to determine differences in the effects of neonatal zidovudine (AZT) vs. nevirapine (NVP) prophylaxis on early longitudinal changes in insulin sensitivity in the first 3 years of life.

HIVInsulin SensitivityDiabetes Mellitus

Ann & Robert H Lurie Children's Hospital of Chicago495 participantsStarted Aug 2016

Gaborone, Botswana

Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions

NCT05354297

ECLIPSE will evaluate the clinical and economic value of OneTouch Solutions in a real world study design. OneTouch Solutions describes a selection of devices and health and wellness solutions that people with diabetes (PWDs) can access online via OneTouch Solutions (Cecelia Health, Fitbit, Noom or Welldoc, each in combination with OneTouch Verio Reflect® blood glucose meter and the OneTouch Reveal® mobile app (or Welldoc app for the Welldoc arm)). ECLIPSE is a large parallel arm digital health study combining advanced blood glucose monitoring solutions with a choice of four different health and wellness applications or services. There are four unique study arms that will run in parallel over one year. The primary (A1c) endpoint for each study arm will be after 6 months and subjects will continue to use the interventions for a full year to generate data on sustained engagement with these products and services, and to collect healthcare utilization and health insurance claims information. Each study arm will differ to some degree in terms of patient baseline demographics (since subjects self-select their own app/intervention) and the experience per arm will be unique, and therefore each study arm will be analysed separately in terms of endpoints and outcomes.

Diabetes Mellitus, Type 2

LifeScan800 participantsStarted Jul 2022

San Mateo, California, United States

Head-to-head Comparison of Empagliflozin and Dapagliflozin

NCT03748810

This open-labeled, prospective, observational, 3-year, clinical study was conducted to compare the effectiveness and safety between empagliflozin (25 mg once daily) and dapagliflozin (10 mg once daily) in patients with inadequately controlled type 2 diabetes despite preexisting triple OAD combination.

Chungbuk National University Hospital600 participantsStarted Jan 2016

Cheonju, North Chungcheong, South Korea

PreviousPage 153 of 394Next